NCT04598555 (PRIME) is a clinical trial in Asthma, sponsored by Chiesi Farmaceutici S.p.A..

Who is sponsoring NCT04598555?

NCT04598555 is sponsored by Chiesi Farmaceutici S.p.A..

Is NCT04598555 still recruiting?

NCT04598555 is currently completed. Last updated 27 September 2022.

Last reviewed 2022-09-27 · How we verify

NCT04598555: PRIME

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Patterns of Care in Mild Asthmatic Patients

Completed Last updated 27 September 2022

What this trial tests

trial in Asthma in 981 participants. Completed in 2 September 2022.

Timeline

25 February 2021

Primary endpoint
2 September 2022

2 September 2022

Quick facts

Lead sponsor	Chiesi Farmaceutici S.p.A.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	981
Start date	25 February 2021
Primary completion	2 September 2022
Estimated completion	2 September 2022
Sites	59 locations across Italy, Spain, Germany, Poland

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Chiesi Farmaceutici S.p.A. — full company profile →

Who can join

Adults 18 to 75, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PRIME study is an observational, Real World Evidence study designed to collect the type of treatments that are currently prescribed to patients with mild asthma and to collect relevant clinical data that could reflect the control of the disease over a 6-month observational period according to the standard clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME study.
Brusselle G, Blasi F, Gessner C, Kuna P, et al · · 2024 · cited 1× · PMID 39351383 · DOI 10.1183/23120541.00174-2024

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Chiesi Farmaceutici S.p.A. trials

Trials by the same sponsor.

NCT07516951 — A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis · Phase 2 · not yet recruiting
NCT07301736 — Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma · Phase 2 · recruiting
NCT07163182 — Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and · Phase 1 · recruiting
NCT06900816 — A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate C · Phase 2 · completed
NCT06892756 — Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04598555 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiesi Farmaceutici S.p.A.
Last refreshed: 27 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing